ipriflavone has been researched along with Disease Models, Animal in 9 studies
ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteolytic bone metastasis is a frequent problem in the treatment of cancer." | 5.31 | Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. ( Akedo, H; Iwasaki, T; Mukai, M; Nakamura, H; Tatsuta, M; Terada, N; Tsujimura, T, 2002) |
| "Ipriflavone (IP) is an isoflavone derivative available in several countries for investigational and/or therapeutic use." | 2.38 | Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. ( Reginster, JY, 1993) |
| "Ipriflavone was reported to be primarily metabolized via hepatic cytochrome P450 (CYP) 1A1/2 and 2C11 in male Sprague-Dawley rats." | 1.35 | Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin. ( Choi, YH; Chung, HJ; Kim, SH; Lee, DY; Lee, I; Lee, MG; Lee, U, 2009) |
| "Osteoporosis was determined by the extent of bone density and by lowering the concentrations of serum Ca2+, P and ALP activity every week." | 1.32 | Studies on the effects of biomedicinal agents on serum concentration of Ca2+, P and ALP activity in osteoporosis-induced rats. ( Kim, SK; Lee, MH; Rhee, MH, 2003) |
| "Osteolytic bone metastasis is a frequent problem in the treatment of cancer." | 1.31 | Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. ( Akedo, H; Iwasaki, T; Mukai, M; Nakamura, H; Tatsuta, M; Terada, N; Tsujimura, T, 2002) |
| "Significant inhibition of bone resorption was also seen in intact animals, provided they rapidly ingested the daily meal." | 1.30 | Ipriflavone inhibits bone resorption in intact and ovariectomized rats. ( Cecchini, MG; Fleisch, H; Mühibauer, RC, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 2 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Lee, DY | 1 |
| Chung, HJ | 1 |
| Choi, YH | 1 |
| Lee, U | 1 |
| Kim, SH | 1 |
| Lee, I | 1 |
| Lee, MG | 1 |
| Iwasaki, T | 1 |
| Mukai, M | 1 |
| Tsujimura, T | 1 |
| Tatsuta, M | 1 |
| Nakamura, H | 1 |
| Terada, N | 1 |
| Akedo, H | 1 |
| Perugini, P | 1 |
| Genta, I | 1 |
| Conti, B | 1 |
| Modena, T | 1 |
| Cocchi, D | 1 |
| Zaffe, D | 1 |
| Pavanetto, F | 1 |
| Kim, SK | 1 |
| Rhee, MH | 1 |
| Reginster, JY | 1 |
| Cecchini, MG | 1 |
| Fleisch, H | 1 |
| Mühibauer, RC | 1 |
| Panteliou, SD | 1 |
| Abbasi-Jahromi, H | 1 |
| Dimarogonas, AD | 1 |
| Kohrt, W | 1 |
| Civitelli, R | 1 |
| Scheiber, MD | 1 |
| Rebar, RW | 1 |
2 reviews available for ipriflavone and Disease Models, Animal
| Article | Year |
|---|---|
Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.
Topics: Animals; Bone Resorption; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Hyperpar | 1993 |
Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy?
Topics: Aged; Animals; Bone Density; Clinical Trials as Topic; Disease Models, Animal; Estrogen Replacement | 1999 |
7 other studies available for ipriflavone and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Injections, | 2009 |
Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model.
Topics: Analgesics; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Divisi | 2002 |
PLGA microspheres for oral osteopenia treatment: preliminary "in vitro"/"in vivo" evaluation.
Topics: Animals; Bone Remodeling; Disease Models, Animal; Drug Carriers; Drug Compounding; Female; Injection | 2003 |
Studies on the effects of biomedicinal agents on serum concentration of Ca2+, P and ALP activity in osteoporosis-induced rats.
Topics: Alkaline Phosphatase; Animals; Antlers; Bone Density; Bone Remodeling; Calcium; Dietary Supplements; | 2003 |
Ipriflavone inhibits bone resorption in intact and ovariectomized rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Bone Remodeling; Bone Resorption; Diet; Disease | 1997 |
Low-frequency acoustic sweep monitoring of bone integrity and osteoporosis.
Topics: Absorptiometry, Photon; Acoustic Stimulation; Analgesics; Animals; Bone and Bones; Bone Density; Dis | 1999 |